TauRx Therapeutics Ltd. Revenue and Competitors

TauRx was established to address one of the world's biggest challenges – beating Alzheimer's and other degenerative brain disorders through a completely new approach. A leader in Alzheimer's research, the company's mission is to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative disorders. TauRx's strong research team, supported through cooperative relationships with multiple academic institutions around the world, has focussed on the tau pathway, believed to be one of the critical causes of neurodegeneration in the brain. The company's novel tau aggregation inhibitors (TAIs) target the formation of tau protein ‘tangles' in the brain and its lead compound LMTX® inhibits aggregation of tau, synuclein, TPD-43 and huntingtin proteins. LMTX® is currently in development for the treatment and prevention of Alzheimer's and bvFTD. TauRx is incorporated in Singapore with primary research and operations in Aberdeen, Scotland.